Amgen Inc (AMGN) 164.30 $AMGN
Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
PR Newswire - 1 hr 17 mins ago
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the Goldman Sachs Conference Center in New York City. Scott Foraker, vice president and general manager of biosimilars at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 164.30 (+1.71)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 11.61 (+0.17), BLCM: 22.65 (+0.19), KITE: 59.98 (+0.20), MRK: 58.34 (+0.59), CLLS: 35.15 (+0.15), XON: 46.30 (+3.30), AMGN: 164.30 (+1.71), JUNO: 60.66 (+4.06)
Midday Glance: Biotechnology companies
AP - Mon Mar 30, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
60 minutes piece highlights promise of cancer-killing viruses
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 11:30AM CDT
ONCY: 0.77 (unch), AMGN: 164.30 (+1.71)
Early Glance: Biotechnology companies
AP - Mon Mar 30, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:30AM CDT
Hospira, Inc. presented data from two studies on a proposed biosimilar, Retacrit.
JNJ: 101.55 (+1.21), ALNY: 107.78 (+3.72), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), HSP: 87.72 (-0.16)
FDA accepts Amgen's Kyprolis sNDA under Priority Review
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 9:18AM CDT
AMGN: 164.30 (+1.71)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), HD: 114.63 (+0.77), RYL: 48.91 (+0.73), ALTR: 42.82 (-1.57), AMGN: 164.30 (+1.71), XOM: 85.63 (+2.05), INTC: 31.46 (-0.54), CELG: 120.02 (+1.34), LEN: 51.49 (+1.06), CVX: 106.90 (+2.62), TOL: 39.21 (-0.01), REGN: 459.78 (+5.28)
FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
PR Newswire - Mon Mar 30, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the conversion of accelerated approval to full approval and expand the current Kyprolis indication. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015.
AMGN: 164.30 (+1.71)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), AMGN: 164.30 (+1.71)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), PCYC: 256.43 (-0.12), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), HON: 104.91 (+1.95), KRFT: 90.61 (+1.51), INTC: 31.46 (-0.54), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), KMX: 69.22 (+2.53), JACK: 97.04 (+0.73), YHOO: 44.95 (-0.15), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), ABBV: 58.24 (+0.59), REGN: 459.78 (+5.28), UNP: 110.09 (+1.65), DK: 39.91 (+1.71), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), AMGN: 164.30 (+1.71), NXPI: 102.43 (+2.51), BA: 152.70 (+3.85), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), HAIN: 64.28 (+0.49), WWAV: 44.64 (-0.59), ZOES: 32.92 (+0.50), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), CNI: 66.23 (+0.08), NDLS: 17.54 (-0.06), MCD: 97.88 (+0.92), AVGO: 130.55 (+2.34)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
M2 - Mon Mar 30, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d4nggb/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering. The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019. CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators. An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market. According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually. Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market. Key Vendors - AbbVie - Astra Zeneca - Biogen Idec - Johnson & Johnson - Takeda Pharmaceutical - UCB Other Prominent Vendors - Amgen - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - CD Pipeline Landscape - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/d4...bal_crohns
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), NVO: 54.68 (+0.84), MRK: 58.34 (+0.59), AMGN: 164.30 (+1.71), NVS: 101.31 (+0.91)
3 Top Stocks for Obamacare Lovers
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 28, 2:03PM CDT
Source: White House on Twitter Obamacare is unquestionably a lightning rod for controversy. Millions of Americans dislike the health reform law, but many also support it. What isn't in dispute, though, is that Obamacare has created quite a few...
HCA: 76.17 (+0.10), CYH: 52.28 (+0.55), AMGN: 164.30 (+1.71), MOH: 66.30 (+0.94), NVS: 101.31 (+0.91)
5 Freakishly Expensive Cancer Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 11:03AM CDT
The cost of cancer treatment is climbing, and healthcare advocates are increasingly worrying that skyrocketing cancer medication costs could take a big toll on the healthcare industry in the coming decade. A recent study conducted by the Memorial...
ESRX: 85.40 (+3.02), AMGN: 164.30 (+1.71), LLY: 73.87 (+0.29), NVS: 101.31 (+0.91)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), GILD: 100.69 (-0.31), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71)
Final Glance: Biotechnology companies
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen
PR Newswire - Fri Mar 27, 8:00AM CDT
Hospira, Inc. (NYSE: HSP), a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, presented two studies that support an evaluation of biosimilarity of its proposed biosimilar, Epoetin Hospira, with the U.S. Food and Drug Administration (FDA) conditionally approved name of RETACRIT(TM), compared to the reference product, Amgen's EPOGEN(TM) (epoetin alfa). These study data were presented at the National Kidney Foundation (NKF) spring meeting in abstracts titled "PK/PD Equivalence of Epoetin Hospira and EPOGEN Following Single Subcutaneous Doses to Healthy Subjects," and "Epoetin Hospira and EPOGEN PK/PD Equivalence Following Multiple Subcutaneous Doses to Healthy Subjects."
AMGN: 164.30 (+1.71), HSP: 87.72 (-0.16)
Portfolio Changes For The First Quarter Of 2015
Alexander J. Poulos - at Seeking Alpha - Thu Mar 26, 8:09PM CDT
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), RE: 176.50 (+2.90), HSY: 102.43 (+0.54), C: 51.64 (+0.64), BPT: 58.95 (-0.53), PCP: 211.58 (-0.60), CCE: 44.71 (+0.71), UPS: 97.27 (+0.68), SLB: 84.48 (+1.17), DEO: 113.05 (-0.19), ZROZ: 126.54 (-0.63), HEDJ: 66.67 (+0.75), FAST: 41.80 (+0.63), V: 65.66 (+0.12), IBM: 162.67 (+2.27), DE: 88.61 (+1.15), GOOGL: 561.13 (+3.58), SYF: 30.29 (+0.23), BK: 40.29 (+0.54), AAPL: 126.37 (+3.12), HTZ: 21.58 (+0.75), AXP: 78.05 (+0.08), EMN: 70.40 (+1.69), AMGN: 164.30 (+1.71), WFC: 54.77 (+0.65), TSM: 23.25 (+0.31), BAC: 15.52 (+0.21), BA: 152.70 (+3.85), ALL: 70.95 (+0.90), PM: 76.86 (+0.07), WBA: 85.99 (+0.70), NVO: 54.68 (+0.84), ESV: 21.12 (-0.16), GILD: 100.69 (-0.31), MCD: 97.88 (+0.92), AMC: 35.52 (+0.57), FLT: 150.83 (+2.27), SBGI: 32.35 (+1.24), VZ: 49.12 (+0.56), CTSH: 63.34 (+0.34), GIS: 56.35 (+1.36), CL: 69.29 (+0.54)
Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer
PR Newswire - Thu Mar 26, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that breast cancer survivor Joan Lunden has been named 2015 Honorary Breakaway from Cancer® Champion as part of a nationwide search to identify 10 Champions who have made a positive impact in their community. Nominations are being accepted for cancer survivors, patients, caregivers and advocates who have inspired those affected by cancer for the chance to win a trip to the 2015 Amgen Tour of California and be recognized during the final day of America's largest and most prestigious professional cycling race.
AMGN: 164.30 (+1.71)
Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference
PR Newswire - 1 hr 17 mins ago
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs Key Debates in Biosimilars conference at 9:05 a.m. ET on Thursday, April 2, 2015, at the Goldman Sachs Conference Center in New York City. Scott Foraker, vice president and general manager of biosimilars at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 164.30 (+1.71)
This Small Biotech Got A Booster Shot On CAR-T Deal
at Investor's Business Daily - Mon Mar 30, 1:15PM CDT
Shares of Intrexon (XON) gapped up on news that the synthetic biotech had formed a collaboration and licensing deal with biopharmaceutical firm Merck KGaA of Darmstadt, Germany, to develop and commercialize CAR-T therapies. Intrexon shares rose 9% to...
ZIOP: 11.61 (+0.17), BLCM: 22.65 (+0.19), KITE: 59.98 (+0.20), MRK: 58.34 (+0.59), CLLS: 35.15 (+0.15), XON: 46.30 (+3.30), AMGN: 164.30 (+1.71), JUNO: 60.66 (+4.06)
Midday Glance: Biotechnology companies
AP - Mon Mar 30, 12:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
60 minutes piece highlights promise of cancer-killing viruses
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 11:30AM CDT
ONCY: 0.77 (unch), AMGN: 164.30 (+1.71)
Early Glance: Biotechnology companies
AP - Mon Mar 30, 9:56AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Hospira Presents Data on Retacrit, an Epogen Biosimilar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:30AM CDT
Hospira, Inc. presented data from two studies on a proposed biosimilar, Retacrit.
JNJ: 101.55 (+1.21), ALNY: 107.78 (+3.72), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), HSP: 87.72 (-0.16)
FDA accepts Amgen's Kyprolis sNDA under Priority Review
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 9:18AM CDT
AMGN: 164.30 (+1.71)
Stock Market News for March 30, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 9:10AM CDT
Benchmarks ended the last trading session of the week on a positive note after Fed Chair Janet Yellen said there was a possibility of a gradual hike in interest rates sometime this year
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), HD: 114.63 (+0.77), RYL: 48.91 (+0.73), ALTR: 42.82 (-1.57), AMGN: 164.30 (+1.71), XOM: 85.63 (+2.05), INTC: 31.46 (-0.54), CELG: 120.02 (+1.34), LEN: 51.49 (+1.06), CVX: 106.90 (+2.62), TOL: 39.21 (-0.01), REGN: 459.78 (+5.28)
FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma
PR Newswire - Mon Mar 30, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. The sNDA is designed to support the conversion of accelerated approval to full approval and expand the current Kyprolis indication. As part of the acceptance, the FDA granted Kyprolis priority review with a Prescription Drug User Fee Act (PDUFA) target action date of July 26, 2015.
AMGN: 164.30 (+1.71)
European regulator validates Biogen's marketing application for Remicade biosimilar
Seeking Alpha - at Seeking Alpha - Mon Mar 30, 7:00AM CDT
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), AMGN: 164.30 (+1.71)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), PCYC: 256.43 (-0.12), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), HON: 104.91 (+1.95), KRFT: 90.61 (+1.51), INTC: 31.46 (-0.54), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), KMX: 69.22 (+2.53), JACK: 97.04 (+0.73), YHOO: 44.95 (-0.15), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), ABBV: 58.24 (+0.59), REGN: 459.78 (+5.28), UNP: 110.09 (+1.65), DK: 39.91 (+1.71), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), AMGN: 164.30 (+1.71), NXPI: 102.43 (+2.51), BA: 152.70 (+3.85), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), HAIN: 64.28 (+0.49), WWAV: 44.64 (-0.59), ZOES: 32.92 (+0.50), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), CNI: 66.23 (+0.08), NDLS: 17.54 (-0.06), MCD: 97.88 (+0.92), AVGO: 130.55 (+2.34)
Global Crohn's Disease (CD) Market 2015-2019: Key Players are AbbVie, Astra Zeneca, Biogen Idec, Johnson & Johnson, Takeda Pharmaceutical & UCB
M2 - Mon Mar 30, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d4nggb/global_crohns) has announced the addition of the "Global Crohn's Disease (CD) Market 2015-2019" report to their offering. The analysts forecast the Global CD market to grow at a CAGR of 2.84% over the period 2014-2019. CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties. This report covers the present scenario and the growth prospects of the Global CD market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators. An increase in strategic collaborations is one key trend being witnessed in the market. As a result of intense competition in the market, vendors are forming strategic alliances to increase their share in the market. According to the report, the high prevalence of CD has led to an increase in the number of medical prescriptions to treat the disease. Globally, the incidence rate for CD varied from 0.30 to 16.50 cases per 100,000 people annually. Further, the report states that the expiry of patents results in the loss of exclusivity leading to a rapid decline in the sales of that specific drug in the market. The expiry of patents of major drugs leads to the development of their generic forms resulting in a fragmented market. Key Vendors - AbbVie - Astra Zeneca - Biogen Idec - Johnson & Johnson - Takeda Pharmaceutical - UCB Other Prominent Vendors - Amgen - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Disease Overview - CD Pipeline Landscape - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/d4...bal_crohns
JNJ: 101.55 (+1.21), BIIB: 431.62 (+1.75), NVO: 54.68 (+0.84), MRK: 58.34 (+0.59), AMGN: 164.30 (+1.71), NVS: 101.31 (+0.91)
3 Top Stocks for Obamacare Lovers
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 28, 2:03PM CDT
Source: White House on Twitter Obamacare is unquestionably a lightning rod for controversy. Millions of Americans dislike the health reform law, but many also support it. What isn't in dispute, though, is that Obamacare has created quite a few...
HCA: 76.17 (+0.10), CYH: 52.28 (+0.55), AMGN: 164.30 (+1.71), MOH: 66.30 (+0.94), NVS: 101.31 (+0.91)
5 Freakishly Expensive Cancer Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 11:03AM CDT
The cost of cancer treatment is climbing, and healthcare advocates are increasingly worrying that skyrocketing cancer medication costs could take a big toll on the healthcare industry in the coming decade. A recent study conducted by the Memorial...
ESRX: 85.40 (+3.02), AMGN: 164.30 (+1.71), LLY: 73.87 (+0.29), NVS: 101.31 (+0.91)
Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
Keith Speights, Brian Orelli, and Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 7:02AM CDT
Relatively few drugs attain the esteemed blockbuster status of $1 billion in annual sales. For those that do, many of them take several years to reach that mark. Gilead Sciences , however, raised the bar with the launch of hepatitis C drug Harvoni....
BLUE: 123.89 (+9.48), BIIB: 431.62 (+1.75), ESRX: 85.40 (+3.02), GILD: 100.69 (-0.31), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71)
Final Glance: Biotechnology companies
AP - Fri Mar 27, 5:10PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), CELG: 120.02 (+1.34)
Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen
PR Newswire - Fri Mar 27, 8:00AM CDT
Hospira, Inc. (NYSE: HSP), a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, presented two studies that support an evaluation of biosimilarity of its proposed biosimilar, Epoetin Hospira, with the U.S. Food and Drug Administration (FDA) conditionally approved name of RETACRIT(TM), compared to the reference product, Amgen's EPOGEN(TM) (epoetin alfa). These study data were presented at the National Kidney Foundation (NKF) spring meeting in abstracts titled "PK/PD Equivalence of Epoetin Hospira and EPOGEN Following Single Subcutaneous Doses to Healthy Subjects," and "Epoetin Hospira and EPOGEN PK/PD Equivalence Following Multiple Subcutaneous Doses to Healthy Subjects."
AMGN: 164.30 (+1.71), HSP: 87.72 (-0.16)
Portfolio Changes For The First Quarter Of 2015
Alexander J. Poulos - at Seeking Alpha - Thu Mar 26, 8:09PM CDT
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), RE: 176.50 (+2.90), HSY: 102.43 (+0.54), C: 51.64 (+0.64), BPT: 58.95 (-0.53), PCP: 211.58 (-0.60), CCE: 44.71 (+0.71), UPS: 97.27 (+0.68), SLB: 84.48 (+1.17), DEO: 113.05 (-0.19), ZROZ: 126.54 (-0.63), HEDJ: 66.67 (+0.75), FAST: 41.80 (+0.63), V: 65.66 (+0.12), IBM: 162.67 (+2.27), DE: 88.61 (+1.15), GOOGL: 561.13 (+3.58), SYF: 30.29 (+0.23), BK: 40.29 (+0.54), AAPL: 126.37 (+3.12), HTZ: 21.58 (+0.75), AXP: 78.05 (+0.08), EMN: 70.40 (+1.69), AMGN: 164.30 (+1.71), WFC: 54.77 (+0.65), TSM: 23.25 (+0.31), BAC: 15.52 (+0.21), BA: 152.70 (+3.85), ALL: 70.95 (+0.90), PM: 76.86 (+0.07), WBA: 85.99 (+0.70), NVO: 54.68 (+0.84), ESV: 21.12 (-0.16), GILD: 100.69 (-0.31), MCD: 97.88 (+0.92), AMC: 35.52 (+0.57), FLT: 150.83 (+2.27), SBGI: 32.35 (+1.24), VZ: 49.12 (+0.56), CTSH: 63.34 (+0.34), GIS: 56.35 (+1.36), CL: 69.29 (+0.54)
Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer
PR Newswire - Thu Mar 26, 3:01PM CDT
Amgen (NASDAQ:AMGN) today announced that breast cancer survivor Joan Lunden has been named 2015 Honorary Breakaway from Cancer® Champion as part of a nationwide search to identify 10 Champions who have made a positive impact in their community. Nominations are being accepted for cancer survivors, patients, caregivers and advocates who have inspired those affected by cancer for the chance to win a trip to the 2015 Amgen Tour of California and be recognized during the final day of America's largest and most prestigious professional cycling race.
AMGN: 164.30 (+1.71)
